aristolochic acid i has been researched along with Ureteral Obstruction in 6 studies
aristolochic acid I: phospholipase A inhibitor
aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 1 |
| Mariappan, N | 1 |
| Megyesi, J | 1 |
| Shank, B | 1 |
| Kannan, K | 1 |
| Theus, S | 1 |
| Price, PM | 1 |
| Duffield, JS | 1 |
| Portilla, D | 1 |
| Scarpellini, A | 1 |
| Huang, L | 1 |
| Burhan, I | 1 |
| Schroeder, N | 1 |
| Funck, M | 1 |
| Johnson, TS | 1 |
| Verderio, EA | 1 |
| Neelisetty, S | 1 |
| Alford, C | 1 |
| Reynolds, K | 1 |
| Woodbury, L | 1 |
| Nlandu-Khodo, S | 1 |
| Yang, H | 1 |
| Fogo, AB | 1 |
| Hao, CM | 1 |
| Harris, RC | 1 |
| Zent, R | 1 |
| Gewin, L | 1 |
| Samarakoon, R | 1 |
| Helo, S | 1 |
| Dobberfuhl, AD | 1 |
| Khakoo, NS | 1 |
| Falke, L | 1 |
| Overstreet, JM | 1 |
| Goldschmeding, R | 1 |
| Higgins, PJ | 1 |
| Lu, H | 2 |
| Bai, Y | 3 |
| Wu, L | 1 |
| Hong, W | 2 |
| Liang, Y | 2 |
| Chen, B | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis[NCT03487861] | 1,000 participants (Anticipated) | Observational | 2017-08-29 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for aristolochic acid i and Ureteral Obstruction
| Article | Year |
|---|---|
Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction.
Topics: Animals; Arginase; Aristolochic Acids; B7-2 Antigen; Collagen Type I; Collagen Type IV; Down-Regulat | 2013 |
Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.
Topics: Animals; Aristolochic Acids; Fibrosis; GTP-Binding Proteins; Male; Mice; Mice, Inbred C57BL; Mice, K | 2014 |
Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells.
Topics: Actins; Animals; Aristolochic Acids; Cells, Cultured; Collagen Type I; Disease Models, Animal; Extra | 2015 |
Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Disea | 2015 |
Inhibition of Macrophage Migration Inhibitory Factor Protects against Inflammation and Matrix Deposition in Kidney Tissues after Injury.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aristolochic Acids; Blotting, West | 2016 |
Transforming growth factor-β1 stimulates hedgehog signaling to promote epithelial-mesenchymal transition after kidney injury.
Topics: Animals; Aristolochic Acids; Cell Line; Disease Models, Animal; Disease Progression; Epithelial-Mese | 2016 |